CervoMed Stock Slides Into Long Weekend as CRVO’s Cash Clock Tests Phase 3 Hopes
CervoMed Inc. shares head into the long U.S. market weekend under pressure, with CRVO ending Friday at $3.06 and down about 11% for the week after a first-quarter update shifted attention back to funding for its planned late-stage dementia trial. That matters now because Nasdaq is closed on Monday for Memorial Day, leaving Tuesday as the next regular session for investors to trade on the update. The pause comes after a rough week for the small-cap biotech, even as broader U.S. indexes finished higher.